Las Acciones de la Farmacéuca Tesaro protagonizaron dias atras un subida de hasta el 110% en Wall Street después de que la compañía informase del progreso de su medicamento experimental para el cáncer de ovario, Niraparib. En particular, el fármaco, en fase 3 y probado en 500 personas, demostró que los pacientes con esta enfermedad no se curaron, pero no empeoraron.
Tesaro (TSRO): It All Comes Down to This Drug .
Ask yourself this: Can Tesaro get its ovarian cancer drug approved in the U.S. and Europe based on the data its latest trial has generated? If the answer is yes, then there’s a good chance that today’s prices will look cheap this time next year.
Posted Date: 7/11/2016 .
TESARO, Inc. recently announced it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $45 million of its common stock. Citigroup, Leerink Partners, Credit Suisse, and Wells Fargo Securities are acting as bookrunners, and Mizuho, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The offering will be made by TESARO pursuant to its automatic shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (SEC) on June 30, 2016. A preliminary prospectus supplement and related prospectus related to the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and related prospectus relating to this offering may be obtained from Citigroup ...